JPRN-UMIN000017057已完成未知
I-131 MIBG(I-131 Meta-Iodobenzylguanidine) radiotherapy for malignant neuroendocrine tumors - I-131 MIBG radiotherapy for malignant neuroendocrine tumors
Kagoshima university hospital Department of Radiology0 个研究点目标入组 25 人开始时间: 2015年4月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Under pregnant or breast feeding Life expectancy less than 1 month Renal disorder (GFR<30ml/min) Limited bone marrow capacity (WBC<3000,platelet<100,000) Understanding and cooperation cannnot be obtained from family members When medical staff determine that treatment cannot be properly carried out.
研究者
相似试验
已完成
1 期
Phase Ib study of 131I-metaiodobenzylguanidine(MIBG) therapy with Valproic Acid(VPA) for high risk or recurrent neuroblastomaIntractable neuroblastomaJPRN-UMIN000012032ational Cancer Research Center Hospital10
已完成
不适用
Prospective study of I-131 3-iodobenzylguanidine radiotherapy for high-risk neuroblastoma; in accordance with the Japanese Advanced Medical Care B program for the anticancer drug with high medical needs.euroblastomaJPRN-UMIN000025045Kanazawa University8
已完成
2 期
131 I-MIBG in Treating Patients With Refractory or Relapsed NeuroblastomaNeuroblastomaNCT00293319University of California, San Francisco164
Available
不适用
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access ProtocolChildhood Metastatic PheochromocytomaNeuroblastomaNCT01163383John Maris
已完成
3 期
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine TumorsNeuroendocrine TumorsMetastases, NeoplasmNCT00037869M.D. Anderson Cancer Center15